What is William Blair’s Forecast for TNYA FY2024 Earnings?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Equities research analysts at William Blair raised their FY2024 earnings per share estimates for Tenaya Therapeutics in a note issued to investors on Wednesday, November 6th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($1.36) for the year, up from their previous estimate of ($1.38). The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.40) per share. William Blair also issued estimates for Tenaya Therapeutics’ Q4 2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.39) EPS and FY2026 earnings at ($1.58) EPS.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.07.

Other equities research analysts have also issued research reports about the company. Chardan Capital dropped their price objective on Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Piper Sandler reaffirmed an “overweight” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Leerink Partners reaffirmed an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 price target on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $14.75.

Tenaya Therapeutics Stock Performance

NASDAQ:TNYA opened at $2.57 on Monday. The firm has a market capitalization of $202.74 million, a price-to-earnings ratio of -1.78 and a beta of 2.34. Tenaya Therapeutics has a 52-week low of $1.61 and a 52-week high of $7.01. The stock has a fifty day moving average of $2.04 and a 200 day moving average of $3.01.

Insider Transactions at Tenaya Therapeutics

In other news, CEO Faraz Ali sold 9,748 shares of Tenaya Therapeutics stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $2.89, for a total value of $28,171.72. Following the transaction, the chief executive officer now owns 188,331 shares in the company, valued at approximately $544,276.59. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders have sold 19,539 shares of company stock worth $56,468. Company insiders own 32.76% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. abrdn plc purchased a new position in Tenaya Therapeutics during the 3rd quarter valued at about $1,063,000. SG Americas Securities LLC purchased a new position in Tenaya Therapeutics during the 3rd quarter valued at about $49,000. Algert Global LLC purchased a new position in Tenaya Therapeutics during the 2nd quarter valued at about $74,000. The Manufacturers Life Insurance Company increased its holdings in Tenaya Therapeutics by 43.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock valued at $72,000 after purchasing an additional 7,000 shares during the period. Finally, Squarepoint Ops LLC increased its holdings in Tenaya Therapeutics by 86.0% during the 2nd quarter. Squarepoint Ops LLC now owns 120,704 shares of the company’s stock valued at $374,000 after purchasing an additional 55,816 shares during the period. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.